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In clinical practice, a risk prediction model is an effective solitary program to predict progno-
sis in particular patient groups. B-type natriuretic peptide (BNP)and N-terminal pro-b-type
natriuretic peptide (NT-proBNP) are widely recognized outcome-predicting factors for
patients with heart failure (HF).This study derived external validation of a risk score to pre-
dict 1-year mortality after discharge in hospitalized patients with HF using the Meta-analysis
Global Group in Chronic Heart Failure (MAGGIC)program data. We also assessed the
effect of adding BNP or NT-proBNP to this risk score model in a Korean HF registry
population.
Method and results
We included 5625 patients from the Korean acute heart failure registry (KorAHF) and
excluded those who died in hospital. The MAGGIC constructed a risk score to predict mor-
tality in patients with HF by using 13 routinely available patient characteristics (age, gender,
diabetes, chronic obstructive pulmonary disorder (COPD), HF diagnosed within the last 18
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months, current smoker, NYHA class, use of beta blocker, ACEI or ARB, body mass index,
systolic blood pressure, creatinine, and EF). We added BNP or NT-proBNP, which are the
most important biomarkers, to the MAGGIC risk scoring system in patients with HF. The out-
come measure was 1-year mortality. In multivariable analysis, BNP or NT-proBNP indepen-
dently predicted death. The risk score was significantly varied between alive and dead
groups (30.61 ± 6.32 vs. 24.80 ± 6.81, p < 0.001). After the conjoint use of BNP or NT-
proBNP and MAGGIC risk score in patients with HF, a significant difference in risk score
was noted (31.23 ± 6.46 vs. 25.25 ± 6.96, p < 0.001).The discrimination abilities of the risk
score model with and without biomarker showed minimal improvement (C index of 0.734 for
MAGGIC risk score and 0.736 for MAGGIC risk score plus BNP or NT-proBNP, p = 0.0502)
and the calibration was found good. However, we achieved a significant improvement in net
reclassification and integrated discrimination for mortality (NRI of 33.4%,p < 0.0001 and IDI
of 0.002, p < 0.0001).
Conclusion
In the KorAHF, the MAGGIC project HF risk score performed well in a large nationwide con-
temporary external validation cohort. Furthermore, the addition of BNP or NT-proBNPto the
MAGGIC risk score was beneficial in predicting more death in hospitalized patients with HF.
Introduction
Heart failure (HF) imposes a great health problem worldwide. The associated risks of HF are
particularly vulnerable in countries with aging populations where diagnosis, treatment, and
prevention of re-hospitalization are difficult [1]. Hospitalized patients with HF have poor
prognosis, but re-hospitalization rates are increasingly, consequently elevating the in-hospital
and post-discharge mortality rates. The prognosis of HF remains poor, and repeated hospitali-
zation exerts a huge cost on national health care budgets and threatens quality of life[2–5].
Therefore, taking urgent measures to predict a patient’s clinical course as early as possible is
necessary by selecting evidence-based management strategies to improve care of patients with
HF. To date, risk stratification in these patients is a challenge [6].
Risk prediction models are frequently used to triage patients and ease treatment decisions,
helping physicians estimate prognosis in a more neutral manner and interpret the conse-
quence of prognosis studies[7, 8].Among all the datasets, the most eminently prognostic infor-
mation could facilitate appropriate implication of monitoring and treatment that improves the
standard of nursing and outcomes of hospitalized patients with HF[7]. Several predictors are
applied in a prediction model to assess the risk of occurrence of a specified event (death, re-
hospitalization) in the future[9].
Recently, the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) has per-
formed a literature-based meta-analysis by collecting each patient data from 30studies includ-
ing six randomized clinical trials. These data consist of important prognostic variables, such as
demographics, medical history, medical treatment, symptom status, clinical variables, labora-
tory variables, and outcome[10,11]. Hence, a risk score was established to predict mortality in
patients with HF from 13 regularly available patient characteristics at a baseline level, and an
easily accessible online calculator was made available (www.heartfailurerisk.org).Tracing risk
stratification depicts a prospective outcome and is beneficial for patients with advanced HF
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(AHF) of multiple etiologies. Meanwhile, risk modeling serves as a comprehensive and conducive
assessment for clinicians and plays a facilitating role to patients and health service provider to
achieve better recognition of likely outcomes[12].MAGGIC also provides an advantage for deter-
mining numerous individual risk factors, such as serum sodium, gender, and survival of patients
with HF with preserved or reduced LVEF[13–15].However, B-type natriuretic peptide(BNP), a
widely recognized outcome-predicting factor for patients with HF, has not been included in a risk
prediction model, as it was only available in less than 25% of the enrolled patients[16, 17].BNP
and N-terminal pro-b-type natriuretic peptide (NT-proBNP) are valuable prognostic predictors
for grading severities and predicting mortality risk in patients with HF[18,19]. Measurement of
serum BNP is essential in guiding decision-making process and predicting patient status, as well
as in establishing therapeutic strategies[20–22]. Thus, considering a major risk factor in a risk
scoring system is necessary to predict important outcome. Although BNP and NT-pro BNP are of
accurate prognosis-predictive ability for hospitalized patients with HF, other clinical factors may
also play pivotal roles in affecting outcomes [23].
An established, simple, cost-effective model with the highest accuracy, which consists of
selective number of predictors, is significant for use in other populations[8]. MAGGIC risk
score in HF was previously conducted and validated in a Swedish population, and an excellent
discrimination was obtained [9]. Nevertheless, the real-world performance of prediction mod-
els for new patient populations and original advancing target populations including Asians is
not consistent[24]. Therefore, in this study, we aimed to derive and externally validate a risk
score to predict 1-year mortality after discharge in hospitalized patients with HF using the
MAGGIC program data. We also assessed the effect of adding BNP or NT-proBNP to this risk
score model in a Korean heart failure registry population.
Methods
Study population
The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort study
designed to measure the outcomes of Korean patients admitted for HF. The registry data consist
of patient demographics, clinical characteristics, and evidence-based treatments[3, 25]. Patients
who had signs or symptoms of HF and met one of the following criteria were eligible for this
study: (1) lung congestion or (2) objective findings of left ventricular systolic dysfunction or struc-
tural heart disease. Patients hospitalized for AHF from 10 tertiary university hospitals throughout
the country were consecutively enrolled from March 2011 to February 2014. The patients were
planned to be followed up until 2018. Data were collected by each site and entered into a web-
based case-report form in the Clinical Data Management System from the Korea National Insti-
tute of Health. Information about patient demographics, medical history, signs, symptoms, results
of laboratory tests, electrocardiogram, echocardiography, medications, hospital course, and out-
comes was collected at admission, discharge, and follow-up (30days, 90days, 180days, 1to 5years
annually).Written informed consent was obtained from each patient. If patients were unable to
give consent due to disease severity, informed consent was obtained from a relative or legal repre-
sentative. In-hospital mortality and the mode of death have been adjudicated by an independent
event committee. The mortality data for patients lost to follow-up were collected from the national
insurance data or national death records. The study protocol was approved by the ethics commit-
tee/institutional review board (IRB) at each hospital.
Measurement of BNP or NT-proBNP
Plasma BNP or NT-proBNP levels were measured at admission for acute HF. Blood sampling
and tests were conducted as routine practice by laboratories at each center certified by the
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Korean Association of Quality Assurance for Clinical Laboratories[26]. Measurement of NT-
proBNP was performed with the electro-chemiluminescence immunoassay method using an
Elecsys 2010 analyzer (Roche Diagnostics) or NT-proBNP assay for Dimension platform, Sie-
mens Medical Solutions Diagnostics. Plasma was tested for BNP using the Biosite Triage assay,
a point-of-care device that uses a fluorescence immunoassay technique (Biosite, San Diego,
CA, USA)[27].
Statistical analysis
Descriptive statistics are used to summarize demographic and clinical characteristics, clinical
care during hospitalization, and outcomes of the patients. Continuous variables are presented
as mean ± standard deviation (SD) and were analyzed with Student’s t-test to demonstrate the
statistical significance of the difference between two groups. Categorical variables are pre-
sented as frequency (percentage) and were analyzed with Chi-square test. The logistic regres-
sion model was applied to verify predictors of all cause mortality. Score discrimination and
calibration were evaluated by the c statistic and Hosmer-Lemeshow statistic [9, 11]. To test the
incremental prognostic utility of B-type natriuretic peptide level (BNP) or N-terminal pro-B-
type natriuretic peptide (NT-proBNP), we used the AUC comparison as DeLoog, net reclassifi-
cation index (NRI) and integrated discrimination improvement (IDI). P-value less than 0.05
were considered statistically significant. All analyses were performed using SAS statistical soft-
ware (version 9.4; SAS Institute Inc., Cary, NC).
Results
Demographic characteristics and clinical profiles
We enrolled 5,625 AHF subjects from 10 tertiary university hospitals in Korea. We excluded
269 patients who died in hospital, 784 patients with missing patient characteristics, and
patients without death information. Finally, we analyzed 4572 patients including 1623 (35.5%)
dead and 2949 (64.5%) alive (Fig 1).
Descriptive statistics for patients who are still alive and patients who died during follow-up are
summarized in Table 1.The mean age was68.42±14.52 years, and 2392(52.32%)were men. The
overall 1-year mortality in the study population was 17.58%. Among the 13 variables, age, creati-
nine (Cr), smoker and diabetes (41.53%),COPD(14.17%), HF duration> 18 month (52.37%) and
NYHA 4(53.73%) as well as not taking medications (ACEI or ARB and beta blocker) were signifi-
cantly higher in patients who died during follow-up compared with those who are alive. Addition-
ally, body mass index (BMI)was almost similar between the 2 groups. However, male gender,
systolic blood pressure (BP), and ejection fraction did not differ significantly between the two
groups. High plasma BNP(>887.9) or NT-proBNP (>4751.05) according to the median value
was significantly higher in the mortality group (61.31% vs 44.63%, p<0.0001), whereas low BNP
or NT-proBNP was higher in the alive group (38.69% vs 55.37%, p<0.0001).
Predictors of mortality
In multivariable analysis, 11 variable included in the MAGGIC score were associated with
mortality. However, when BNP or NT-pro-BNP were associated with MAGGIC. ejection frac-
tion could not predict mortality (Table 2).Here 11variables(age, male sex, BMI,SBP, diabetes,
HF duration > 18 months, NYHA(2–4),Cr, ACEI or ARB, and beta blocker, along with high
BNP or NT-proBNP) were independent predictors in multivariable analysis(Table 2). How-
ever, smoker and COPD were non-significantly associated with mortality in both groups. The
risk score was significantly different between alive and dead groups (30.61 ± 6.32 vs.
MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) HF risk score validation for predicting mortality
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24.80 ± 6.81, p<0.001). After the conjoint use of BNP or NT-proBNP and MAGGIC risk score
in patients with HF, the risk score was also significantly different (31.23 ± 6.46 vs. 25.25 ± 6.96,
p<0.001) (Table 3).There were strongly significantly difference between them [0.61
(0.59~0.64) for death group and 0.45 (0.43~0.47) for alive group].
Validation of the risk score models
In this study, we selected 13 predictor variables from the multivariable model to formulate a
risk score. Good discrimination abilities were found,with a C-indexof 0.734 from the risk
score model to predict 1-year mortality. Hosmer-Lemeshow goodness of fit test for risk score
mortality indicated a good calibration (p = 0.5559) by plotting predicted versus observed mor-
tality using 10 groups (Fig 2). Additionally, the predicted mortality rates corresponded with
the observed mortality rates in each decile.
Effect of adding natriuretic peptide
The addition of BNP or NT-proBNP to the MAGGIC risk score using the 13 variables resulted in
minimal improvement(C index of 0.734 for MAGGIC risk score and 0.736 for MAGGIC risk
score plus BNP or NT-proBNP, p = 0.0502).However, we achieved a significant improvement in
net reclassification and integrated discrimination for mortality (NRI of 33.4%,p<0.0001 and IDI
of 0.002, p<0.0001) (Table 4).
Discussion
This study demonstrates the performance of the MAGGIC project HF risk score using 13 vari-
ables by external validation to predict 1-year mortality after discharge in Korean hospitalized
Fig 1. Selection of the study population. This study enrolled 5625 patients. We excluded 269patients who died in
hospital, 784 patients with missing patient characteristics, and patients without death information. Finally, we analyzed
4572 patients including 1623 (35.5%) dead and 2949 (64.5%) alive.
https://doi.org/10.1371/journal.pone.0206380.g001
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patients with HF. We found that the discrimination and calibration were good for the MAG-
GIC risk score. This risk score is useful to predict mortality after discharge for hospitalized
patients with HF. Furthermore, the addition of BNP or NT-proBNP to the MAGGIC risk
score showed significant improvement in risk reclassification of patients and minimal
improvement in discrimination ability.
HF is a complex and fatal medical condition that progresses rapidly with escalating aging
population and causes considerable morbidity, mortality, and re-hospitalization, resulting in a
tremendous burden on the global healthcare system [28–30]. Physicians always need to deter-
mine the best therapy for high-risk patients and make estimation of risk in patients by inte-
grating patient characteristics, clinical signs, and laboratory tests[8].Prediction is naturally
inconsistent. Although a physician assigns a relative weight to each variable, which relies on
his previous experiences, personal beliefs, clinical judgment, as well as current mood, it could
be inaccurate and ambiguous. To determine an individual’s cardiac mortality risk score in
daily clinical practice, adding points assigned for predictors that exist in a patient is only
required. For this reason, the MAGGIC risk score is beneficial for busy clinicians and nurses.
Using the 13 available baseline variables, including age, EF, NYHA class, serum Cr, diabetes,
systolic BP, BMI, HF duration, current smoker, COPD, male gender, evidence-based medica-
tion beta blocker, and ACE inhibitor or ARBs, can construct the risk score and identify the
risks of hospitalized patients easily at low cost. In this MAGGIC score, each variable was inde-
pendently associated with mortality, except COPD and smoker.
Table 1. Descriptive statistics for baseline variables.
variables Total Death Alive p-value
N = 4572 N = 1623(35.5%) N = 2949 (64.5%)
age 68.42±14.52 74.30±11.54 65.18±14.97 < .0001
Gender (Male) 2392(52.32%) 783(48.24%) 1397(47.37%) 0.5722
BMI 23.35±3.90 22.41±3.71 23.86±3.91 < .0001
Current smoker Current smoker 812 (17.76%) 213(13.12%) 599(20.31%) < .0001
Ex-smoker 982(21.48%) 386(23.78%) 596(20.21%)
Never smoker 2778(60.76%) 1024(63.09%) 1754(59.48%)
SBP 133.0±30.34 132.3±30.63 133.4±30.17 0.2448
DM 1598 (34.95%) 674(41.53%) 924(31.33%) < .0001
NYHA 2 688(15.05%) 176(10.84%) 512(17.36%) < .0001
3 1675 (36.64%) 575(35.43%) 110(37.30%)
4 2209(48.32%) 872(53.73%) 1337(45.34%)
Ejection fraction 38.37±15.73 38.54±15.73 38.27±15.73 0.5747
COPD 515 (11.26%) 230(14.17%) 285(9.66%) < .0001
HF duration > 18 month 1924 (42.08%) 850(52.37%) 1074(36.42%) < .0001
Creatinine (μmol/L) 127.62±121.09 149.2±126.7 115.8±116.2 < .0001
Beta blocker Yes 2423(53%) 740(45.59%) 1683(57.07%) < .0001
No 2149(47%) 883(54.41%) 1226(42.93%)
ACEI or ARB Yes 3219(70.41%) 1061(65.37%) 2158(73.18%) < .0001
No 1353 (29.59%) 562 (34.63%) 791(26.82%)
BNP or NTproBNP < median 2261(49.45%) 628(38.69%) 1633(55.37%) < .0001
�median 2311(50.55%) 995(61.31%) 1316(44.63%)
Values are expressed as mean±standard deviation or n (%). BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; HF, heart failure; COPD, chronic
obstructive pulmonary disease; SBP, systolic blood pressure; EF, ejection fraction; creatinine;New York Heart Association (NYHA) BNP, brain natriuretic peptide.
Angiotensin converting enzyme inhibitors (ACE inhibitors)angiotensin receptor blocker(ARB)
https://doi.org/10.1371/journal.pone.0206380.t001
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Several risk stratification models that are used to predict mortality in hospitalized patients
with HF have limitations. For example, the Seattle Heart Failure Model and the CHARM-
model use not readily available variables. The former requires lymphocyte count, uric acid,
and total cholesterol, and the latter requires atrial fibrillation, cardiomegaly, and pulmonary
edema. Meanwhile, in the HF-ACTION predictive risk score model, inclusion of exercise
duration on the baseline cardiopulmonary exercise test and serum urea nitrogen, which
require difficult estimations, is necessary[31–33].Moreover, in assessing long-term mortality,
other predictive models are used, but included participants from clinical trials. The models
also rely on not readily available variables in clinical care, such as peak exercise oxygen con-
sumption for the Heart Failure Survival Score model; and hemoglobin, GGT, eGFR, 12-lead
ECG, and 24-h Holter monitoring variables including non-sustained VT and frequent VPBs,
Table 2. Multivariate analysis using variables included in the MAGGIC score.
MAGGIC score MAGGIC score+BNP or NTproBNP
variables OR 95% CI p-value OR 95% CI p-value
age 1.056 1.049~1.062 < .0001 1.055 1.048~1.061 < .0001
Gender (male) 1.28 1.077~1.521 0.005 1.339 1.125~1.573 0.001
BMI 0.925 0.908~0.943 < .0001 0.933 0.915~0.951 < .0001
Current smoker Current smoker 0.883 0.709~1.099 0.5265 0.87 0.698~1.085 0.4475
Ex-smoker 0.938 0.771~1.142 0.926 0.760~1.127
Never smoker 1 - 1 -
SBP 0.995 0.993~0.997 < .0001 0.995 0.992~0.997 < .0001
DM 1.481 1.286~1.704 < .0001 1.474 1.280~1.698 < .0001
NYHA 2 1 - 0.0018 1 - 0.0108
3 1.341 1.080~1.665 1.301 1.047~1.618
4 1.464 1.186~1.806 1.385 1.120~1.712
Ejection fraction 0.995 0.990~1.000 0.033 0.998 0.993~1.003 0.4067
COPD 1.124 0.919~1.376 0.2555 1.149 0.938~1.407 0.1789
HF duration > 18 month 1.583 1.381~1.813 < .0001 1.564 1.364~1.793 < .0001
Creatinine 1.002 1.002~1.003 < .0001 1.002 1.001~1.002 < .0001
Beta blocker Yes 1 - < .0001 1 - < .0001
No 1.394 1.216~1.597 1.385 1.207~1.588
ACEI or ARB Yes 1 - 0.0006 1 - 0.0006
No 1.3 1.120~1.508 1.299 1.119~1.508
BNP or NTproBNP < median - - - 1 - < .0001
�median 1.476 1.276~1.708
Values are expressed as mean±standard deviation or n (%). BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; HF, heart failure; COPD, chronic
obstructive pulmonary disease; SBP, systolic blood pressure; EF, ejection fraction; creatinine;New York Heart Association (NYHA) BNP, brain natriuretic peptide.
Angiotensin converting enzyme inhibitors (ACE inhibitors)angiotensin receptor blocker (ARB)
https://doi.org/10.1371/journal.pone.0206380.t002
Table 3. Risk score according to death.
Death Alive p-value
N = 1623 (35.5%) N = 2949 (64.5%)
Maggic score 30.61 ± 6.32 24.80 ± 6.81 < .0001
Maggicscore+BNP or NTproBNP 31.23 ± 6.46 25.25 ± 6.96 < .0001
Difference (95%CI) 0.61 (0.59~0.64) 0.45 (0.43~0.47) < .0001
Withinp-value < .0001 < .0001
https://doi.org/10.1371/journal.pone.0206380.t003
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for the MUSIC risk score model[34, 35]. Although these predictive models are informative
and important for research purposes, their drawbacks limit their use in daily clinical practice.
By contrast, the MAGGIC project HF risk score has several advantages and is superior to other
HF mortality risk models. Itis targeted for a great number of population-based patients with
manifold demographic characteristics regardless of LV systolic function and can be used for
nationwide contemporary external validation cohort. Thus, this model is extensively pertinent
and appealing as it contains nearly a modest number of variables regularly collected during
admission[9]. MAGGIC risk score can be calculated by entering admission data into an online
risk calculator (www.heartfailurerisk.org).This calculator can estimate1-year all-cause mortal-
ity for patients with HF. It is not only easily understandable and beneficial to physicians, but
also helpful for patients and relatives[11].
The MAGGIC projectincluded39,372 patients from 30 studies. Of these studies, 6 were ran-
domized controlled trials (24,041 patients) and the remaining 24 were registries (15,331
patients).Approximately 40% of patients died during a median follow-up of 2.5 years.The six
largest studiescontributed76% of patients and 76% of deaths [11]. Recently, another study per-
formed the MAGGIC risk score in a Swedish population and found excellent discrimination.
However, good calibration was not found as moderate increase in low-risk patients and depre-
ciation of high-risk patients accounted for the 3-year mortality risk[9]. In this present study,
we observed good discrimination and calibration for MAGGIC risk score in hospitalized
patients with HF derived from the KorAHF after discharge. Discharge is often the first step of
Fig 2. Observed vs.Model-predicted 1-year mortality in risk groups: Hosmer-Lemeshow goodness of fit test for
risk score mortality indicated a good calibration (p = 0.5559), the predicted mortality rates corresponded with the
observed mortality rates in each decile.
https://doi.org/10.1371/journal.pone.0206380.g002
Table 4. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) for specific
models using the BNP.
Values p-value
C-index (95%CI)
Maggic score 0.734 (0.720~0.749) -
Maggicscore+BNP or NTproBNP 0.736 (0.721~0.750) 0.0502
NRI (95% CI)
Category-free NRI (%) 33.4% (27.4%~39.3%) < .0001
% of events correctly reclassified 23%
% of non-events correctly reclassified 11%
IDI (95% CI) 0.002 (0.001~0.003) < .0001
https://doi.org/10.1371/journal.pone.0206380.t004
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treatment progress and initial assessment for prediction of prognosis. We adopted the risk
score to patients with HF after discharge from hospital.
This study is the first to use the MAGGIC risk score of patients with HFin a population in
Korea, which is part of East Asia. Some differences exist in the baseline clinical characteristics
and co-morbidity between Western and East Asian countries[36].Several studies reported that
the analytical histories of IHD and hypertension in Koreawere45.4% and 43.6%, respectively,
which were considerably lower than in the high-income Western nations[37]. On the contrary,
the prevalence of hypertension as a co-morbidity of patients with HF is widely varied (39.2%
to 77.6%) in Japan than in other studies, such as in the Acute Decompensated Heart Failure
Syndromes registry (71%),the Organized Program to Initiate Lifesaving Treatment in Hospi-
talized Patients with Heart Failure (71%),and the Euro-Heart Failure Survey II (63%)[38–41].
Although the prevalence of HF is lower in Korea (1.53%) compared with that in the USA
(2.2%) or other Western and European nations, the increase in aging population and adoption
of a Western life style promote the growth of HF prevalence in East Asian countries, including
Korea, China, and Japan[37, 42].With gender consideration, male is the most classic demo-
graphic risk factor for the development of HF, along with older age, ethnicity, and low socio-
economic state, in East Asia [43].The prevalence of overweight/obesity is much lower(21.6–
26.2%) in Southeast Asia than in the UK (66.7%) and USA (69.6%). However, the recent preva-
lence of blood glucose/diabetes as a notable risk factor is higher in Asian countries than in the
UK and USA[44].During the follow-up period, the clinical effect of evidenced-based medica-
tion between Western and Asian countries was also different[45]. Therefore, establishment of
MAGGIC HF risk score model is not only important for Korean population but also for other
Asian countries.
BNP and NT-proBNP are the most powerful prognostic factors; they are expected to serve
as an important basis for diagnosis and play a crucial role in therapeutic decision-making pro-
cess[22]. High plasma BNP or NT-proBNP at admission predicts greater risk of outcomes in
hospitalized patients with HF[22, 46]. On the contrary, we added BNP or NT-proBNP to the
MAGGIC risk score and found minimal improvement in discrimination (C index of 0.734 for
MAGGIC risk score and 0.736 for MAGGIC risk score plus BNP or NT-proBNP, p = 0.0502).
In multivariable analysis, we observed that high natriuretic peptide level was significantly asso-
ciated with mortality. Furthermore, when we used new statistical analysis methods (NRI and
IDI indices), BNP or NT-proBNP (NRI of 33.4%, p <0.0001 and IDI of 0.002, p<0.0001)
showed the greatest increase in discrimination and net reclassification for mortality. Based on
this study, we suggest that the validated risk score is readily generalizable, and the addition of
BNP or NT-proBNPto the MAGGIC risk score was beneficial in predicting more death. There-
fore, a quick and cost-effective important indicator is established to anticipate adverse events
in patients with HF. This indicator supports the performing cardiologist and referring clini-
cian to take direct care and improve communication with patients with HF about their prog-
nosis[46].
Study limitations
This cohort study has several limitations. First, its design had several inherent limitations
including selection bias and missing values. Second, we did not use MAGGIC risk score in-
hospital patients with unstable health condition during admission. Thus, we excluded in-hos-
pital mortality, and analysis was considered after discharge of patients. Third, although in-hos-
pital mortality and post-discharge mortality were confirmed by an independent event
committee, causes of post-discharge mortality are unknown. We could not differentiate car-
diovascular mortality and causes of re-hospitalization, which were not validated. Fourth, we
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did not perform the specific categories of BNP or NTproBNP levels to be widely used as a
prognostic score. We could not also validate and compare MAGGIC risk score with other risk
score such as 3C-HF score which is widely used to predict 1-year mortality using routinely
available predictors. Finally, we evaluated short-term mortality (1-year mortality), and the bio-
marker natriuretic peptide(BNP or NT-proBNP)was only used in this risk score. The measure-
ment time and median value of BNP and NT-proBNP were different.
Conclusions
In the KorAHF, the MAGGIC project HF risk score performed well in a large nationwide con-
temporary external validation cohort. Furthermore, addition of BNP or NT-proBNPto the
MAGGIC risk score was beneficial in predicting more death in hospitalized patients with HF.
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